NDA 021782 · Takeda Pharms USA
Rozerem
Ramelteon · Oral · Melatonin Receptor Agonist
NovelLast checked: Nov 20, 2026Latest source record: Nov 3, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Jul 22, 2005
Approved uses
4
Original approval plus efficacy supplements
Registered trials
77
21 Phase 3, 0 recruiting
FAERS reports
7,425
4,086 serious, 808 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 15, 2026.
ROZEREM ® is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14) ] . ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. ( 1 )
Mechanism: Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT 1 and MT 2 receptors and relative selectivity over the MT 3 receptor. The activity of ramelteon at the MT 1 and MT 2 receptors is believed to contribute to its sleep-promoting properties, as these receptors, acted upon by endogenous melatonin, are thought to be involved in the maintenance of the circadian rhythm underlying the normal sleep-wake cycle. Ramelteon has no appreciable affinity for the GABA receptor complex or for receptors that bind neuropeptides, cytokines, serotonin, dopamine, noradrenaline,...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2008 Supplement 9 · Efficacy LabelLetter
- Oct 20, 2008 Supplement 8 · Efficacy LetterLabel
- Oct 20, 2008 Supplement 10 · Efficacy LabelLetter
- Jul 22, 2005 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
1 products under this application
- ROZEREM · RAMELTEON 8MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ramelteon" as an intervention, any sponsor and status, largest first.
- Efficacy of Ramelteon in Subjects With Chronic InsomniaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00671086 · 1,213 participants · Start Feb 2003 · Primary completion Sep 2004
Drug: Ramelteon; Ramelteon · For: Sleep Initiation and Maintenance Disorders
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 122 sites in all
- Efficacy of Ramelteon in Adults With Chronic InsomniaPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT00672724 · 1,081 participants · Start Feb 2005 · Primary completion Aug 2005
Drug: Ramelteon; Placebo · For: Chronic Insomnia
Sites: Mesa, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 43 sites in all
- Ramelteon in Adults With Chronic InsomniaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00671567 · 848 participants · Start Dec 2002 · Primary completion Sep 2003
Drug: Ramelteon; Ramelteon and 1 more · For: Chronic Insomnia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 70 sites in all
- Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic InsomniaPivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00671255 · 829 participants · Start Dec 2002 · Primary completion Jan 2004
Drug: Ramelteon; Ramelteon and 1 more · For: Chronic Insomnia
Sites: Columbiana, Alabama; Mobile, Alabama; Muscle Shoals, Alabama · 115 sites in all
- Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I DisorderPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT01467713 · 642 participants · Start Dec 2011 · Primary completion Mar 2015
Drug: Ramelteon SL; Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Dothan, Alabama; Muscle Shoals, Alabama · 156 sites in all
- Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia.Pivotal-lookingCompleted
TakedaTakeda (TAK)
NCT00414102 · 552 participants · Start Oct 2006 · Primary completion Sep 2007
Drug: Ramelteon; Placebo · For: Chronic Insomnia
Sites: Phoenix, Arizona; Tucson, Arizona; Hot Springs, Arkansas · 52 sites in all
- Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 DisorderPivotal-lookingTerminated
TakedaTakeda (TAK)
NCT01677182 · 535 participants · Start Aug 2012 · Primary completion Aug 2014
Drug: Ramelteon; Placebo · For: Bipolar Disorder
Sites: Birmingham, Alabama; Anaheim, California; Glendale, California · 104 sites in all
- Delirium Reduction With RamelteonPivotal-lookingStatus unknown
Centennial Medical CenterAcademic, hospital or other
NCT05069428 · 506 participants (planned) · Start Mar 26, 2023 · Primary completion Mar 2025
Drug: Ramelteon 8mg · For: Delirium
Sites: Nashville, Tennessee
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective927
- initial insomnia448
- somnolence422
- insomnia402
- middle insomnia390
- nausea342
- fatigue291
- dizziness278
- headache262
- off label use249
- diarrhoea229
- poor quality sleep219
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 80 |
| 2006 | 743 |
| 2007 | 1,151 |
| 2008 | 601 |
| 2009 | 115 |
| 2010 | 204 |
| 2011 | 214 |
| 2012 | 201 |
| 2013 | 156 |
| 2014 | 176 |
| 2015 | 348 |
| 2016 | 408 |
| 2017 | 423 |
| 2018 | 380 |
| 2019 | 383 |
| 2020 | 281 |
| 2021 | 311 |
| 2022 | 248 |
| 2023 | 258 |
| 2024 | 248 |
| 2025 | 304 |
| 2026 | 192 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Mar 19, 2026
Rozerem, Tablet, 8 mg (NDC 64764-805-10). Product is expected to be available through February 2027.
To Be Discontinued · updated Mar 19, 2026
Rozerem, Tablet, 8 mg (NDC 64764-805-30). Product is expected to be available through June 2027.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Rozerem (Ramelteon)
2024 spending
$735K
Beneficiaries
504
1,774 claims
Per beneficiary
$1,459
$11.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,802,537 |
| 2021 | $1,776,820 |
| 2022 | $1,355,109 |
| 2023 | $1,012,351 |
| 2024 | $735,418 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.
De Crescenzo F, D'Alò GL, Ostinelli EG, et al. · Lancet 2022 · Network Meta-Analysis, Systematic Review
- Melatonin Use in the ICU: A Systematic Review and Meta-Analysis.
Tang BHY, Manalo J, Chowdhury SR, et al. · Crit Care Med 2025 · Systematic Review, Meta-Analysis
- Efficacy of melatonin and ramelteon for the acute and long-term management of insomnia disorder in adults: A systematic review and meta-analysis.
Maruani J, Reynaud E, Chambe J, et al. · J Sleep Res 2023 · Meta-Analysis, Systematic Review
- Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
McElroy H, O'Leary B, Adena M, et al. · J Manag Care Spec Pharm 2021 · Comparative Study, Network Meta-Analysis
- Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.
Stinton C, McKeith I, Taylor JP, et al. · Am J Psychiatry 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy and safety of each class of sleep medication for major depressive disorder with insomnia symptoms: A systematic review and meta-analysis of double-blind randomized controlled trials.
Maruki T, Takeshima M, Yoshizawa K, et al. · Psychiatry Clin Neurosci 2025 · Systematic Review, Meta-Analysis
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.